Ray Manneh Kopp
Overview
Explore the profile of Ray Manneh Kopp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angel M, Freile B, Rodriguez A, Cayol F, Manneh Kopp R, Rioja P, et al.
JCO Glob Oncol
. 2024 Sep;
10:e2400072.
PMID: 39348607
Purpose: This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC). Patients And Methods: This study is a retrospective, multicenter cohort study of patients with mPC...
2.
Santini D, Li H, Roviello G, Park S, Grande E, Kucharz J, et al.
Target Oncol
. 2024 Sep;
19(6):893-903.
PMID: 39289313
Background: Therapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients who have progressive disease as the best response, "primary refractory" (P),...
3.
Ciccarese C, Buttner T, Cerbone L, Zampiva I, Monteiro F, Basso U, et al.
Int J Cancer
. 2024 Sep;
155(11):2036-2046.
PMID: 39243397
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that...
4.
Rizzo M, Soares A, Grande E, Bamias A, Manneh Kopp R, Lenci E, et al.
Sci Rep
. 2024 Aug;
14(1):19802.
PMID: 39187558
The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on...
5.
Choueiri T, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al.
N Engl J Med
. 2024 Aug;
391(8):710-721.
PMID: 39167807
Background: Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. Methods: In a phase 3, multicenter, open-label, active-controlled trial, we enrolled participants with...
6.
Rizzo A, Marques Monteiro F, Urun Y, Massari F, Park S, Bourlon M, et al.
Target Oncol
. 2024 Aug;
19(5):747-755.
PMID: 39107651
Background: The benefit of immune checkpoint inhibitors (ICIs) for poor performance status patients with advanced urothelial carcinoma (UC) remains unknown. Objective: In the present sub-analysis of the ARON-2 study, we...
7.
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, et al.
Clin Exp Metastasis
. 2024 Jun;
41(5):655-665.
PMID: 38850317
Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy...
8.
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, et al.
Target Oncol
. 2024 May;
19(4):587-599.
PMID: 38704759
Background: About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role of cytoreductive...
9.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia J, Basso U, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):106.
PMID: 38634928
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or...
10.
Manneh Kopp R, Galanternik F, Schutz F, Kater F, Ramos-Esquivel A, Neciosup S, et al.
JCO Glob Oncol
. 2024 Jan;
10:e2300244.
PMID: 38271646
Purpose: Urothelial cancer accounts for approximately 3% of new cancer cases worldwide, with a high burden of disease in countries with medium and low human development indexes where its incidence...